The neuroscience data analytics company Ixico Ltd. is many things to many people, but it is not a start-up. CEO of two years Giulio Cerroni stresses that almost before we start. IXICO is also not an especially young company, formed some 14 years ago as a spin-out from several UK universities, it has been trading for 13 years, and in 2018 (year-end September 30) reported an underlying revenue increase of 41% and a record-high revenue total of £5.4m ($7.02m). It has been AIM-listed since its 2013 reverse takeover of Phytopharm.
The company’s performance to date has been good, but it is not good enough for Cerroni. On assuming the chief executive role in 2017, he set about drafting a strategic...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
